Which statement about growth factor support in high-risk regimens is true?

• A. It shortens neutropenia duration and reduces infection risk
• B. It cures cancer
• C. It causes immunosuppression
• D. It is unnecessary in high-risk regimens

Answer: (A)

Growth factor support with G-CSF is used in high-risk chemotherapy to speed up neutrophil recovery. By stimulating the bone marrow to produce neutrophils, it shortens the duration of neutropenia, which is the period when the body is most vulnerable to infection. Shorter neutropenia means fewer days with very low neutrophil counts, resulting in a lower risk of febrile neutropenia and related infections, and often fewer hospitalizations. This is a supportive measure, not a cancer cure, and it does not cause immunosuppression; it helps the immune system rebound faster. In high-risk regimens, this approach reduces FN incidence and supports delivering planned chemotherapy doses. Hence, the statement that growth factor support shortens neutropenia duration and reduces infection risk is true.